Abstract 2469
Background
Soft-tissue sarcomas (STS) are life-threatening diseases, for which more efficient therapeutic options are necessary. Trabectedin (T) is an anti-tumor drug approved for the treatment of advanced STS. Synergistic drug combinations could improve T results in STS patients. Rapamycin (R) is an mTOR pathway inhibitor. Synergy with T has been described in ovary clear cell carcinoma. Of note, R suppresses DNA double-strand breaks repair, thus generating the perfect set-up for T activity. Altogether, we hypothesize that T+R combination (T+R) is synergistic in STS, and that mTOR inhibition enhances T activity.
Methods
Human STS cell lines (n = 9) were treated with increasing doses of T (1x10-7M to 1x10-11M) and/ or R (1x10-9 to 1x10-11) to determine IC50 and combination index (CI) values. Cells were initially exposed to R, 2 hours later T was added, under the assumption that R pre-treatment favors T cytotoxicity. Cell viability, at 72 h, was measured by MTS assay. Apoptosis was determined by Western Blot for PARP and Caspase 3 cleavage. In vivo experiments were performed in immunocompetent 3-methylcolanthrene fibrosarcoma mice: T was administrated via IV (0.15 mg/kg; q7dx1) and R via IP (0.50 mg/kg; q7dx2). Body weight and tumor volume were measured every 2 days for 15 days of treatment. Tumors were collected for analysis (snap frozen and paraffin embedding).
Results
T+R was synergistic in all STS cell lines: CP0024 primary leiomyosarcoma and 93T449 liposarcoma cell lines showed strong synergism with CI at the ED50 of 0.129 and 0.027, respectively. This synergy was followed by an increase of PARP and Caspase 3 cleavage. The synergism was confirmed in vivo: mice treated with R+T showed tumor growth delay in comparison to the drugs alone (p < 0.05). Stable disease was achieved in 7 out of 7 mice.
Conclusions
R+T is synergic in STS and deserves exploration in clinical setting. Further research will reveal the mechanisms underlying this synergy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Javier Martín Broto.
Funding
PharmaMar.
Disclosure
D.S. Moura: Research grant / Funding (institution): PharmaMar; Research grant / Funding (institution): Eisai; Research grant / Funding (institution): Novartis; Travel / Accommodation / Expenses: PharmaMar; Travel / Accommodation / Expenses: Eisai. M. Lopez-Alvarez: Travel / Accommodation / Expenses: Eisai. N. Hindi: Travel / Accommodation / Expenses: PharmaMar; Research grant / Funding (institution): Eisai; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): PharmaMar; Honoraria (self): PharmaMar. J. Martin-Broto: Research grant / Funding (institution): PharmaMar; Research grant / Funding (institution): Eisai; Research grant / Funding (institution): Novartis; Honoraria (self): PharmaMar; Honoraria (self): Lilly; Honoraria (self): Novartis; Speaker Bureau / Expert testimony: PharmaMar. All other authors have declared no conflicts of interest.
Resources from the same session
5107 - Tolerability of PCV in Low Grade Glioma: a Real World Experience
Presenter: Razia Aslam
Session: Poster Display session 1
Resources:
Abstract
6171 - Molecular EGFR/PD-L1 profile of glioblastoma: Hints for therapeutic strategies
Presenter: Wojciech Szopa
Session: Poster Display session 1
Resources:
Abstract
4418 - Role of Intraoperative MRI (iMRI) in neurosurgery, potential imaging tool for maximizing gross total resection (GTR) rate of CNS tumours.
Presenter: Shweta Wadhwa
Session: Poster Display session 1
Resources:
Abstract
4791 - Tumor related impairments of neurocognitive functions in patients with brain metastases
Presenter: Lei Wen
Session: Poster Display session 1
Resources:
Abstract
5372 - Is radiation therapy influencing Alzheimer’s in Brain and Head and Neck Cancers?
Presenter: Anas Saad
Session: Poster Display session 1
Resources:
Abstract
2329 - Mature Treatment Results of 120 Cases of Acoustic Neuroma Treated with Cyberknife at a single institution.
Presenter: Shawn Malone
Session: Poster Display session 1
Resources:
Abstract
3207 - A phase II/III trial of high-dose, intermittent sunitinib in patients with recurrent glioblastoma: the STELLAR study
Presenter: Cyrillo Brahm
Session: Poster Display session 1
Resources:
Abstract
3589 - CNS penetration and Preliminary Efficacy of Sacutizumab Govitecan in Breast Brain Metastasis and Glioblastoma: A Surgical Study
Presenter: Andrew Brenner
Session: Poster Display session 1
Resources:
Abstract
1969 - Wedge resection with omission of lymph node dissection as an optional treatment strategy in octogenarians or older with early stage non-small cell lung cancers
Presenter: Takahiro Mimae
Session: Poster Display session 1
Resources:
Abstract
5116 - Characterization of lung tumorspheres reveals cancer stem-like cells potential targets and prognostic markers in non-small cell lung cancer
Presenter: Alejandro Herreros Pomares
Session: Poster Display session 1
Resources:
Abstract